Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer

11 Aug 2003

Abstract excerpt

BACKGROUND: Relatives of BRCA1 and BRCA2 mutation carriers have long been proposed by epidemiological studies to have an increased risk of developing prostate cancer. In the Ashkenazi Jewish (AJ) population, the existence of 3 frequent founder mutations, 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 greatly facilitates screening for carriers. METHODS: We tested 146 AJ men with confirmed diagnoses of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA gene mutations in cancer
Share to Prostate Cancer Diagnosis and Treatment
Share to Prostate Cancer Treatment and Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 12911837
DOI: 10.1186/1471-2350-4-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancerPMID 12911837Read ↗

BRCA mutations and risk of prostate cancer in Ashkenazi Jews.Semantic proximity Read ↗

Germline BRCA mutations denote a clinicopathologic subset of prostate cancer.Semantic proximity Read ↗

Common mutations in BRCA1 and BRCA2 do not contribute to early prostate cancer in Jewish men.Semantic proximity Read ↗

Associations of high-grade prostate cancer with BRCA1 and BRCA2 founder mutations.Semantic proximity Read ↗

The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel.Semantic proximity Read ↗

A twofold increase in <i>BRCA</i> mutation related prostate cancer among Ashkenazi Israelis is not associated with distinctive histopathologySemantic proximity Read ↗

Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer.Semantic proximity Read ↗

Incidence of BRCA1 and BRCA2 non-founder mutations in patients of Ashkenazi Jewish ancestry.Semantic proximity Read ↗

BRCA1 and BRCA2 pathogenic variants and prostate cancer risk: systematic review and meta-analysis.Semantic proximity Read ↗

Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women.Semantic proximity Read ↗

Identifying Ashkenazi Jewish BRCA1/2 founder variants in individuals who do not self-report Jewish ancestry.Semantic proximity Read ↗

Identifying Ashkenazi Jewish <i>BRCA1/2</i> founder variants in individuals who do not self-report Jewish ancestrySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.